

EHA-SWG Scientific Meeting

"Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemia"


Submit your abstract before February 10th 2025.

Why attend EHA-SWG?

The meeting will provide a thorough update on susceptibility factors to sAML, including germ-line and acquired molecular lesions, as well as the role of the bone marrow microenvironment.

In addition, clinically important aspects such as sAML following childhood malignancies, leukemogenic effects of drugs as well as prevention/ surveillance strategies will be discussed. Finally, the meeting will also focus on special situations including sAML following gene therapy, CAR-T cell therapy, and AML of donor origin in the context of allogeneic stem cell transplantation.

More information



Meeting Chairs:

- Konstanze Döhner
- Paresh Vyas
- Maria-Teresa Voso

Meeting Topics:

The meeting will cover the following topics:

- Germ-line and acquired predisposition to sAML
- Clonal progression from other myeloid diseases (BM-failure s., MDS, MPN)
- sAML development as a result of cancer treatment (after chemotherapy, CAR-T, gene therapy)
- Genetic characteristics of sAML
- Treatment of sAML
- Allogeneic stem cell transplantation (donor-derived sAML)

April 25-26, 2025 Berlin, Germany